Press Releases

Mentice Receives Grant from Sweden’s Innovation Agency to Improve Synthetic Image Generation

Mentice has received a 3 million SEK grant from the Swedish government agency for innovation, Vinnova, to improve realism in Mentice virtual reality software environment with a focus on synthetic image generation. Mentice will be a part of a joint European research project called the TASTI project, financed by Vinnova within the Eureka Xecs cluster. 

Mentice Launches New Website

Sweden – Gothenburg, October 27, 2022. Mentice, a world leader in virtual and physical simulation solutions for Image-guided Interventional Therapies, is pleased to announce the launch of its new website www.mentice.com.  

Mentice publishes the company’s interim report for the period July – Sept 2022

CONTINUOUS STRONG DEMAND FROM THE HOSPITAL MARKE

Mentice and Acandis GmbH announce a 3-year agreement for Mentice Ankyras clinical support software solutions at a value of 8.9mSEK.

Sweden-Gothenburg and Germany-Pforzheim, October 25, 2022 (https://news.cision.com/mentice-ab)

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on October 26 at 10:00 CEST

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2023

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2023 has been appointed.

Mentice AB (publ) receives an order of USD 620,000 for simulation solutions and development services

Sweden-Gothenburg, August 22, 2022 (https://news.cision.com/mentice-ab)

Mentice publishes the company’s interim report for the period April – June 2022

The acquisition of Ankyras is finalized and a large order in the quarte

Mentice AB (STO: MNTC) completes the acquisition of ANKYRAS

Sweden-Gothenburg, 30th June, 2022 (https://news.cision.com/mentice-ab)

Mentice receives an initial order of USD 1.93million for simulation solutions and development services from a global medtech company

Sweden-Gothenburg,  June 29, 2022 (https://news.cision.com/mentice-ab)

June 9, 2022 Mentice AB acquires all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L.

In accordance with the press release published on 9 June 2022, Mentice AB (publ) (“Mentice” or the “Company”), has entered into an agreement (the “Agreement”) to acquire all assets relating to the software solution Ankyras (“Ankyras”) from Galgo Medical S.L. (“Galgo”) (the “Acquisition”), which was conditional on the receipt of external financing. In accordance with the press release published on 9 June 2022, Mentice has received such external financing through a directed new share issue and thereby fulfilled the condition of the financing in the Agreement.

Stockholm June 9, 2022 Mentice AB completes a directed new share issue of approximately SEK 60 million which was significantly oversubscribed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Mentice AB (“Mentice” or the “Company”) has, in accordance with the intention announced in the Company’s press release earlier today, carried out a directed new share issue of 800,000 shares, corresponding to approximately SEK 60 million (the “Directed New Share Issue”). The subscription price of the shares in the Directed New Share Issue amounts to SEK 75 per share through an accelerated bookbuilding procedure carried out by Pareto Securities AB ("Pareto Securities"). A large number of Swedish and international institutional investors, including Bure Equity AB, Fjärde AP-fonden (AP4), Handelsbanken Fonder and TIN Fonder, participated in the Directed New Share Issue which was significantly oversubscribed.

Stockholm June 9, 2022 Mentice AB explores the conditions for carrying out a directed share issue of approximately SEK 60 million

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Mentice AB (“Mentice” or the “Company”) hereby announces intention to carry out a directed new issue of shares of approximately SEK 60 million directed to Swedish and international institutional investors (the “Directed New Share Issue”). The Directed New Share Issue will be carried out to, among other things, finance the acquisition of all assets relating to the software solution Ankyras from the Spanish company Galgo Medical S.L. (the “Acquisition”) which the Company announced today in a separate press release. Mentice has engaged Pareto Securities AB (“Pareto Securities”) as Sole Manager and Bookrunner to investigate the conditions for the Directed New Share Issue through an accelerated bookbuilding procedure.

Mentice AB intends to acquire all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L. June 9, 2022

Mentice AB (publ) (“Mentice” or the “Company”), a leading provider of high-tech solutions for decision support and productivity with the medical field of image guided interventional therapies, announces the intention to acquire all assets of the Ankyras software suite (“Ankyras”) from Galgo Medical S.L. (“Galgo”) for an amount of EUR 1.80 million (approximately SEK 18.78 million[1]) with a possible additional purchase amount of EUR 0.975 million (approximately SEK 10.17 million[1]), and with a total purchase consideration amounting to approximately EUR 2.775 million (about SEK 28.95 million[1]) to be paid in cash (the “Acquisition”). The agreement and the completion of the said agreement is conditioned upon Mentice financing the transaction, which is planned to be performed through a directed new share issue. [1] EUR/SEK = 10.4330

Communique from annual general meeting in Mentice AB

Press release 2022-04-27

Mentice publishes the company’s interim report for the period January–March 2022

A strong start for the year with continued overall growth

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on April 27 at 10:00 CEST

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.

Annual shareholders’ meeting in Mentice AB

The shareholders in Mentice AB, reg. no. 566556-4241, (the “Company”), are hereby invited to attend the annual shareholders’ meeting to be held on 27 April 2022 at 3.00 p.m. at the Company’s premises at Odinsgatan 10 in Gothenburg

PRESS RELEASE March 16, 2022 Mentice receives order of ten (10) VIST simulator systems in China for a value exceeding 500,000 USD

Mentice, a world leader in simulation solutions for image-guided interventional therapies, announced today that Siemens Healthineers China via an official importation agent, has placed an order of ten (10) Mentice VIST simulator packages including the Siemens Virtual Patient Link software to be bundled with the Corindus CorPath GRX Robitic system sales in China

Global Influential Clinical Body Exclusively Endorses Mentice Cardiology Bifurcation Simulation

European Bifurcation Club (EBC), an esteemed medical organization specialized in the treatment of coronary bifurcation lesions, today announced their endorsement of advanced technical skills adoption and proficiency-based continuous learning. The endorsement is unique for Mentice patented VIST® G7+ Coronary Advanced training module that provides an approved patient-free learning environment for Interventional Cardiologists in the field of bifurcation stenting.

Mentice Appoints Jan Grund Pedersen as New VP of Strategic Alliances & Business Development

Mentice, a world leader in simulation solutions for image-guided interventional therapies, today announced the appointment of Jan Grund Pedersen as the Vice President for Strategic Alliances & Business Development. 

Mentice publishes the company’s year-end report for the period January–December 2021

Continued strength with net sales growth above 30% despite the pandemic

Mentice’s CEO Göran Malmberg to present the company’s Year-end Report Q4 2021 at a webcast conference call on February 3rd at 9:30 CET

Mentice AB (STO: MNTC) announces that the company will present its year-end report via a webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.

Siemens Healthineers to include Mentice VIST ® simulators with Corindus CorPath GRX Robotic PCI system (CorPath GRX) in China.

Mentice and Siemens Healthineers China announce that Mentice VIST ® Virtual Patient simulators will be included with the sale of every Corindus CorPath GRX Robotic system (CorPath GRX) in China on an initial 3-year agreement, starting 2022.

PRESS RELEASE October 28, 2021 Mentice publishes the company’s interim report for the period January–September 2021

Continued growth through Q3 and for the year to dat

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on October 28 at 9:30 CEST

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.

PRESS RELEASE October 18, 2021 Mentice receives order of total SEK 7.0 million from ABBOTT

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has through its fully owned subsidiary Mentice Inc entered into an agreement with ABBOTT Inc. to provide simulation solutions for training of interventional devices

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2022

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2022 has been appointed

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2022

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2022 has been appointed

Mentice publishes the company’s interim report for the period January–June 2021

Mentice delivers record level of sales for the second quarter and first half yea

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on July 22 at 9:30 CEST

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund.

Mentice receives order of total SEK 5.9 million from Baylis Medical Company

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on interventional procedures, has entered into an agreement with Baylis Medical Company (“Baylis”) to provide simulation solutions

Mentice appoints Gunilla Andersson as Chief Financial Officer (CFO)

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on image guided interventions, appoints Gunilla Andersson as CFO, effective September 1[st], 2021

Thomas Jefferson University Hospitals and Mentice to establish a Simulation Center of Excellence for Interventional Radiology

Jefferson to introduce Mentice’s virtual patient technology into IR training and virtual reality simulations used by physicians to improve their clinical practice.

Communique from annual general meeting in Mentice AB (publ)

An annual general meeting was held in Mentice AB on 6 May 2021. Below follows a summary of the resolutions made at the meeting

Mentice publishes the company’s interim report for the period January–March 2021

Strongest order intake in Mentice's history despite the corona pandemi

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on April 28 at 9:30 CET

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund.

Mentice appoints Pontus Appelqvist as Vice President and GM for Asia Pacific

Mentice AB (STO: MNTC), a leading supplier of high-tech solutions for simulation in the medical sector, with a focus on endovascular procedures, today announced the appointment of Pontus Appelqvist as Vice President and General Manager for Asia Pacific. Pontus has more than 20 years of enterprise leadership experience in driving new technologies to market within Asia. In his previous role, his direction led to multiple years of triple-digit growth by adapting innovative Augmented Reality (AR), Virtual Reality (VR), and interactive solutions for education and training in the region

Notice to attend the Annual shareholders’ meeting in Mentice AB

The shareholders of Mentice AB, reg. no. 566556-4241, (the “Company”), are hereby given notice to attend the annual shareholders’ meeting to be held on 6 May 2021 by completing a form for postal voting. A shareholder that wishes to attend the annual shareholders’ meeting may only do so by completing the form for postal voting and mailing it to the Company prior to the meeting, no physical attendance is allowed

Mentice publishes the company’s year-end report for the period January–December 2020

Strong order intake and substantial improvement of the company’s order boo

Mentice’s CEO Göran Malmberg to present the company’s year-end 2020 report at a webcast conference call on February 4 at 9:30 CET

Mentice AB (STO: MNTC) announces that the company will present its year-end report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund.

Mentice to enhance its organization with several new key positions

Mentice AB (publ), a leading supplier of high-tech solutions for simulation in the medical sector, with focus on endovascular procedures, has announced changes to its organization. Several new key positions have been created, aimed at improving Mentice’s regional presence in the market.

Issuance of new shares in Mentice AB (publ) has been registered with the Swedish Companies Registration Office

Regarding the acquisition of the assets from Vascular Simulations Inc 571,974 shares have been issued at a subscription price of SEK 86.16 and regarding the acquisition of the assets from EQIP Inc, 9,469 shares have been issued at a subscription price of SEK 84.28

Mentice publishes the company’s interim report for the period July–September 2020

Two exciting acquisitions and strong performance in the medical device industry segmen

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2021

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee for the company’s Annual General Meeting 2021 has been appointed

Mentice receives order of total SEK 6.1 million from Stryker

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has entered into an agreement with Stryker US to provide simulation solutions for its Neurovascular division

Mentice receives order of total SEK 7.1 million from ABBOTT

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, has entered into an agreement with ABBOTT to provide simulation solutions for training of interventional devices

Mentice to acquire assets of health technology startup EQIP, Inc., adding technology for logging and analysis of clinical procedures

Mentice AB (publ) has today signed an agreement to acquire all substantial assets of EQIP, Inc. (EQIP), a startup medtech company based in Jacksonville, Florida. The purchase price amounts to 180 KUSD (approx. 1.6 MSEK) with a possible additional purchase price of maximum 70 KUSD (approx. 0.6 MSEK). Purchase price will be paid with a directed new shares issue in Mentice AB and cash payment

Mentice entered into an agreement to acquires all substantial assets of the US medical technology company Vascular Simulations Inc.

Mentice AB (publ), a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures acquires the substantial assets from Vascular Simulation Inc (Vascular Simulation). The purchase price amounts to 5.6 million USD (approx. 48 million SEK) with a possible additional purchase price of maximum 0.4 million USD (approx. 3.5 million SEK). Purchase price will be paid with a directed new shares issue in Mentice AB

Mentice engages Pareto Securities as liquidity provider

Mentice AB (publ), a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, engages Pareto Securities as liquidity provide

Mentice receives order of total SEK 5.5 million from BD (former Bard Peripheral Vascular)

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from BD (former Bard Peripheral Vascular) for the segment Medical Device Industry relating to solutions for physician training in the peripheral vascular area. The order covers system sales for a total order value of SEK 5.5 million and will be delivered during the third quarter 2020

Mentice publishes the company’s interim report for the period January–June 2020

Solid performance for the quarter and the first half of the year despite the effects of the pandemi

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on August 13 at 9:30 CET

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund

Mentice receives order of total SEK 7.0 million from Edwards Lifesciences

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from Edwards Lifesciences for the segment Medical Device Industry relating to solutions for the Mitral/Tricuspid Valve therapy areas. The order covers system sales and development to be delivered during the fourth quarter 2020. The total order value amounts to SEK 7.0 million and will be accounted for in the order book for the third quarter 2020

Mentice receives order of total SEK 6.0 million from Abbott EP

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, receives order from Abbott EP for the segment Medical Device Industry. The order covers system sales and development to be delivered during the third quarter 2020. The total order value amounts to SEK 6.0 million and will be accounted for in the order book for the second quarter 2020

Communique from annual general meeting in Mentice AB (publ)

Press release 2020-05-2

Mentice Launches Seventh Generation Platform to Help Transition Endovascular Therapy in a COVID-19 Era

VIST® G7 Introduces a Virtual Patient to Help Doctors Acquire, Retain, and Enhance Skills in the Absence of Procedural Volume.  

The Nomination Committee of Mentice AB has resolved to amend it previous proposition regarding Item 2 of the agenda for the Annual General Meeting to be held on May 27[th] 2020

The Nomination Committee of Mentice AB has resolved to amend it previous proposition regarding Item 2 of the agenda for the Annual General Meeting to be held on May 27th 2020 with regards to the proposed chairman of the meeting 202

Mentice publishes the company’s interim report for the period January–March 2020

Encouraging signs for the medium to long-term outlook, while the uncertainty in 2020 remain

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on May 14 at 10:00 CET

Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund

Annual shareholders’ meeting in Mentice AB

PRESS RELEAS

Mentice publishes the company’s year-end report for the period January–December 2019

Encouraging signs for 2020, despite continued lag in the medical device industry in Q

Mentice’s CEO Göran Malmberg to present the company’s year-end report 2019 at a webcast conference call on February 27 at 10:00 CET

Mentice AB (STO: MNTC) announces that the company will present its year-end report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund

Mentice publishes preliminary net sales and order intake figures for January–December 2019

Today, Mentice AB (STO: MNTC) publishes preliminary (unaudited) net sales and order intake figures for January–December 2019. The net sales figures are roughly in line with the revised full year forecast in the Q3 interim report, (with a 4-5% decrease in net sales), while order intake is 20% lower compared to last year. To address the current lag in order intake and improve overall sales performance, CEO Göran Malmberg is assuming direct responsibility for global sales activities

Mentice appoints Honeybadger as the company’s IR communication partner

Mentice AB (STO: MNTC), a world leader in simulation solutions for endovascular therapies, will strengthen its market communication together with the IR communication firm Honeybadger. An IR communication plan for 2020 is now being finalised, including a newsletter with in-depth information on Mentice’s business operations

Nomination committee has been appointed for Mentice AB (publ) Annual General Meeting 2020

Mentice AB (STO: MNTC), a world leader in simulation solutions for endovascular therapies, announces that the nomination committee for the company’s Annual General Meeting 2020 has been appointed

Mentice publishes the company’s interim report for the period January–September 2019

Continued expansion, but the medical device industry is laggin

Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on November 25 at 15:00 CET

Mentice AB (STO: MNTC) announces that the company will present its interim reports via webcast conference calls starting from the current quarter, with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Elisabet Lund

Mentice Q2 interim report 2019

Mentice AB (publ.) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, presents its interim report for second quarter 2019

Extraordinary shareholders’ meeting held on August 28, 2019 elects three new board members in Mentice AB

The extraordinary shareholders’ meeting held in Mentice AB on August 28, 2019, elected three additional board members

Extraordinary shareholders’ meeting of Mentice AB

The shareholders in Mentice AB, reg. no. 556556-4241, are hereby invited to attend the extraordinary shareholders’ meeting to be held on Wednesday 28 August 2019 at 3.00 pm. at the company’s premises at Odinsgatan 10 in Gothenburg

Nomination committee propose new board members in Mentice AB prior to convening an Extraordinary Shareholders’ Meeting on August 28, 2019

Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, announces that the nomination committee proposes that the board be extended with three members to a total of seven members. The nomination committee intends to suggest the election of Denis Gestin, Gösta Johannesson and David Ballard

Exercise of over-allotment option and end of stabilisation period

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE

Mentice and Siemens Healthineers bring a virtual patient to the angio-suite

Mentice's offering was substantially oversubscribed – trading in the share on Nasdaq First North Premier commences tomorrow

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE